Table 6.
Summary of median days on first‐, second‐ and third‐line therapy; patients with psoriasis who initiated and discontinued new therapy during the registry
| Ustekinumab | Infliximab | Adalimumab | Etanercept | |
|---|---|---|---|---|
| First‐line therapy | ||||
| All patients, N | 361 | 63 | 402 | 289 |
| Days on therapy | 613 (448–894) | 676 (309–1034) | 569 (239–894) | 565 (246–1024) |
| Discontinued, n (%) | 31 (8.6) | 16 (25.4) | 151 (37.6) | 127 (43.9) |
| Days on therapy | 316 (199–589) | 305 (188–758) | 258 (129–537) | 215 (120–413) |
| Second‐line therapy | ||||
| All patients, N | 566 | 93 | 622 | 155 |
| Days on therapy | 621 (365–947) | 446 (213–779) | 510 (230–981) | 317 (121–738) |
| Discontinued, n (%) | 106 (18.7) | 51 (54.8) | 250 (40.2) | 75 (48.4) |
| Days on therapy | 302 (183–490) | 316 (162–821) | 244 (127–475) | 153 (53–281) |
| Third‐line therapy | ||||
| All patients, N | 551 | 103 | 197 | 71 |
| Days on therapy | 592 (323–985) | 416 (242–769) | 457 (185–841) | 337 (128–679) |
| Discontinued, n (%) | 129 (23.4) | 49 (47.6) | 90 (45.7) | 35 (49.3) |
| Days on therapy | 287 (155–476) | 312 (172–513) | 204 (95–414) | 166 (74–309) |
Days on therapy are presented as median (interquartile range).